Abstracts Archive - Page 1059 of 2425 - ACR Meeting Abstracts

Abstract Number: 816 • 2018 ACR/ARHP Annual Meeting
Development of Thoracic Aortic Aneurysms in Patients with Polymyalgia Rheumatica: Underdiagnosed Giant Cell Arteritis?
Nicolas Martin Marin Zucaro¹, Marina Scolnik², Florencia Beatriz Mollerach³, Valeria Scaglioni², Luciano Fernando Lo Giudice¹, Jose Maximiliano Martinez P⁴, John Fredy Jaramillo Gallego¹ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are close-related entities. Imaging studies have suggested that subclinical inflammation of the large arteries is frequent…
Abstract Number: 817 • 2018 ACR/ARHP Annual Meeting
Current Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis
Antoine G. Sreih¹, Dianne Shaw², Kalen Young³, Cristina Burroughs⁴, Joyce Kullman⁵, Kirthi Machireddy⁶, Carol A. McAlear¹, George Casey³ and Peter A. Merkel⁷, ¹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ²University of North Carolina, Chapel Hill, NC, ³Vasculitis Foundation, Kansas city, MO, ⁴University of South Florida, Tampa, FL, ⁵Vasculitis, Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite recent advancements in the evaluation and management of vasculitis, patients with vasculitis continue to encounter diagnostic delays. These delays are often associated…
Abstract Number: 818 • 2018 ACR/ARHP Annual Meeting
Visual Involvement in Giant Cell Arteritis: A Prospective Multi Center Study
Faidra Laskou¹, Tin Aung², Dawn Gayford³, Siwalik Banerjee², Cynthia S. Crowson⁴, Eric L. Matteson⁵ and Bhaskar Dasgupta⁶, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Southend-On-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Southend-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, westcliff-on-Sea, United Kingdom, ⁴Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom
Background/Purpose: Under reporting of visual impairment attributable to GCA is likely; certificates of visual impairment do not include GCA as a category. Delayed presentation, recognition…
Abstract Number: 819 • 2018 ACR/ARHP Annual Meeting
Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Sivakumar Mambakkam Rajappa¹ and Krishnamurthy Venkataraman², ¹Rheumatology and Immunology, GLB Hospitals, Chennai, India, ²Rheumatology, Apollo Speciality Hospitals, Chennai, India
Background/Purpose: Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars…
Abstract Number: 820 • 2018 ACR/ARHP Annual Meeting
Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis – Revisited: A 20-Year Population-Based Study From Sweden
Pavlos Stamatis¹, Carl Turesson², Jan-Åke Nilsson² and Aladdin Mohammad³, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: To investigate the incidence rate and seasonal variation of biopsy-proven giant cell arteritis (GCA) in a well-defined population in southern Sweden. Methods: The study…
Abstract Number: 821 • 2018 ACR/ARHP Annual Meeting
Comparison of Aortitis Vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm Repair
Laarni Quimson¹, Bryan Rea² and Rennie L. Rhee³, ¹Internal Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Comparison of Aortitis vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm RepairBackground/Purpose: Distinguishing aortitis-induced aneurysms from more common non-inflammatory aortic aneurysms is…
Abstract Number: 822 • 2018 ACR/ARHP Annual Meeting
Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis
Andrea D. Gloor¹, Daniel Yerly², Jennifer L. Cullmann³, Sabine Adler¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Department of Biomedical Research, University of Bern, Bern, Switzerland, ³Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is an unmet need for tools to quantify local disease activity in TAK.Methods: Sera of 21 TAK patients, aged between 18 and 56…
Abstract Number: 823 • 2018 ACR/ARHP Annual Meeting
Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings
Luigi Boiardi¹, Pierluigi Macchioni², Francesco Muratore³, Mariagrazia Catanoso², Alberto Cavazza⁴, Pamela Mancuso⁵, Luca Cimino⁶, Giovanna Restuccia⁷ and Carlo Salvarani⁸, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁴Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Interinstitutional Epidemiology Unit, Azienda USL di Reggio Emilia (Local Health Authority) and Azienda Ospedaliera IRCCS di Reggio Emilia,, Reggio Emilia, Italy, ⁶Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, ⁸Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy
Background/Purpose: To correlate survival with clinical, laboratory and histopathological findings in a population based cohort of patients with biopsy-proven giant cell arteritis (GCA) living in…
Abstract Number: 824 • 2018 ACR/ARHP Annual Meeting
Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa
Michele Iudici¹, Pierre Quartier², Christian Pagnoux³, Etienne Merlin⁴, Christian Agard⁵, Achille Aouba⁶, Pascal Roblot⁷, Pascal Cohen¹, Benjamin Terrier¹, Luc Mouthon¹, Loïc Guillevin¹ and Xavier Puéchal¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, ³Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁴CHU, Clermont-Ferrand, France, ⁵Nantes Hôtel Dieu, Nantes, France, ⁶Caen, Caen, France, ⁷CHU, Poitiers, France
Background/Purpose: To investigate differences between childhood (cPAN)- and adult-onset polyarteritis nodosa (aPAN) patients. Methods: cPAN patients’ clinical findings at onset and outcomes were compared to…
Abstract Number: 825 • 2018 ACR/ARHP Annual Meeting
Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study
Ummugulsum Gazel¹, Ahmet Omma², Alper Sari³, Dondu Uskudar Cansu⁴, Ayten Yazici⁵, Ayse Cefle⁵, Cemal Bes⁶, Omer Karadag⁷, Haner Direskeneli⁸ and Fatma Alibaz-Oner¹, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology, Osmangazi University, School of Medicine, Eskısehir, Turkey, ⁵Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁶Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁷Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁸Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: IgA Vasculitis is a leukocytoclastic vasculitis involving small vessels with depositions of immune complexes containing IgA. IgA Vasculitis is a predominantly pediatric vasculitis. There…
Abstract Number: 826 • 2018 ACR/ARHP Annual Meeting
Does Anti-Glomerular Basement (anti-GBM) Antibody Positivity Correlate with Relapse in Patients with Anti-GBM Disease?
Nicole Droz¹, Alexis Katz², John Sedor³ and Rula A Hajj-Ali^1,4, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Nephrology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Anti-GBM disease is characterized by rapidly progressive glomerular nephritis with or without pulmonary hemorrhage. It is usually monophasic in nature and disease severity correlates…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 828 • 2018 ACR/ARHP Annual Meeting
Medium and Small-Sized Vessel Involvement in Hypereosinophilic Syndrome
Julien Rohmer¹, Matthieu Groh², Maxime Samson³, Jonathan London⁴, Marie JACHIET⁵, Diane Rouzaud⁶, Antoinette Perlat⁷, Romain Paule⁸, Felipe SUAREZ⁹, Jean-Emmanuel Kahn¹⁰, Loïc Guillevin¹¹ and Benjamin Terrier¹², ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Internal medicine, France, Paris, France, ²Internal Medicine, Foch, Suresnes, France, ³Dijon University Hospital, Dijon, France, ⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁵Dermatology department, St Louis Hospital, Paris, France, ⁶Université Paris-Diderot, Paris, France, ⁷Internal medicine, CHU de Rennes, Rennes, France, ⁸Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁹Hematology Department, Necker Hospital, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ¹¹Medecine Interne, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Primary systemic vasculitis, especially eosinophilic granulomatosis with polyangiitis and polyarteritis nodosa, can be associated with blood and tissue eosinophilia. Conversely, eosinophilia in the context…
Abstract Number: 829 • 2018 ACR/ARHP Annual Meeting
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs
Mohamed Tharwat Hegazy¹, Walaa Allam², Mohamed A Hussein¹, Naguib Zoheir³, Luca Quartuccio⁴, Patrice Cacoub⁵, Wahid Doss⁶, Mona I. Ellawindi⁷, Mary Fawzy¹, Loïc Guillevin⁸, Ahmed El Ray⁹, Maissa El Said El Raziky^10,11, Magdy El Serafy⁶, Sherif El Khamisy^2,12 and Gaafar Ragab¹, ¹Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Center for Genomics, Zewail City of Science and Technology, Giza, Egypt, Giza, Egypt, ³Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁶Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁷Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁸Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁹Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ¹⁰Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ¹¹Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ¹²Krebs Institute, University of Sheffield, Sheffield, S10 2TN, UK, Sheffield, United Kingdom
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs Background/Purpose: Direct Acting Antiviral (DAA) agents were shown to be effective…
Abstract Number: 830 • 2018 ACR/ARHP Annual Meeting
Primary Central Nervous System Vasculitis with Tumor-like Presentation
Carlo Salvarani¹, Robert D. Brown Jr.², Teresa J. H. Christianson³, Caterina Giannini⁴, John Huston III⁵ and Gene G. Hunder⁶, ¹Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²Department of Neurology, Mayo Clinic, Rochester, MN, ³Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, ⁴Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: The aim of this study was to determine the frequency of ML in a large cohort of patients with PCNSV and compare the presenting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].